Literature DB >> 30108731

The synthesis, biological evaluation and structure-activity relationship of 2-phenylaminomethylene-cyclohexane-1,3-diones as specific anti-tuberculosis agents.

Muzafar Ahmad Rather1,2, Ali Mohd Lone3, Bisma Teli3,4, Zubair Shanib Bhat1,4, Paramjeet Singh5, Mubashir Maqbool1, Bashir Ahmad Shairgojray3, Mohd Jamal Dar4,5, Shajrul Amin2, Syed Khalid Yousuf3,4, Bilal A Bhat3,4, Zahoor Ahmad1,4.   

Abstract

The present study utilised whole cell based phenotypic screening of thousands of diverse small molecules against Mycobacterium tuberculosis H37Rv (M. tuberculosis) and identified the cyclohexane-1,3-dione-based structures 5 and 6 as hits. The selected hit molecules were used for further synthesis and a library of 37 compounds under four families was synthesized for lead generation. Evaluation of the library against M. tuberculosis lead to the identification of three lead antituberculosis agents (37, 39 and 41). The most potential compound, 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione (39) showed an MIC of 2.5 μg mL-1, which falls in the range of MICs values found for the known antituberculosis drugs ethambutol, streptomycin and levofloxacin. Additionally, this compound proved to be non-toxic (<20% inhibition at 50 μM concentration) against four human cell lines. Like first line antituberculosis drugs (isoniazid, rifampicin and pyrazinamide) this compound lacks activity against general Gram positive and Gram negative bacteria and even against M. smegmatis; thereby reflecting its highly specific antituberculosis activity.

Entities:  

Year:  2017        PMID: 30108731      PMCID: PMC6072485          DOI: 10.1039/c7md00350a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  17 in total

1.  High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.

Authors:  Chitra Rani; Rukmankesh Mehra; Rashmi Sharma; Reena Chib; Priya Wazir; Amit Nargotra; Inshad Ali Khan
Journal:  Tuberculosis (Edinb)       Date:  2015-07-31       Impact factor: 3.131

Review 2.  Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.

Authors:  Ujjini H Manjunatha; Paul W Smith
Journal:  Bioorg Med Chem       Date:  2014-12-24       Impact factor: 3.641

Review 3.  Resistance to rifampicin: a review.

Authors:  Beth P Goldstein
Journal:  J Antibiot (Tokyo)       Date:  2014-08-13       Impact factor: 2.649

Review 4.  HIV and COPD: a conspiracy of risk factors.

Authors:  Umesh G Lalloo; Sandy Pillay; Rosie Mngqibisa; Sabeer Abdool-Gaffar; Anish Ambaram
Journal:  Respirology       Date:  2016-05-30       Impact factor: 6.424

Review 5.  Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

Authors:  Stephen K Field
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

6.  Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.

Authors:  Lee Jia; Joseph E Tomaszewski; Colleen Hanrahan; Lori Coward; Patricia Noker; Gregory Gorman; Boris Nikonenko; Marina Protopopova
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

7.  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors:  Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

Review 8.  Tuberculosis drug discovery in the post-post-genomic era.

Authors:  Benoit Lechartier; Jan Rybniker; Alimuddin Zumla; Stewart T Cole
Journal:  EMBO Mol Med       Date:  2014-01-08       Impact factor: 12.137

Review 9.  New Antituberculosis Drugs: From Clinical Trial to Programmatic Use.

Authors:  Gina Gualano; Susanna Capone; Alberto Matteelli; Fabrizio Palmieri
Journal:  Infect Dis Rep       Date:  2016-06-24

Review 10.  Delamanid expanded access novel treatment of drug resistant tuberculosis.

Authors:  Roxana Rustomjee; Alimuddin Zumla
Journal:  Infect Drug Resist       Date:  2015-10-29       Impact factor: 4.003

View more
  1 in total

1.  Synthesis and in vitro evaluation of substituted 3-cinnamoyl-4-hydroxy-pyran-2-one (CHP) in pursuit of new potential antituberculosis agents.

Authors:  Zubair Shanib Bhat; Hafiz Ul Lah; Muzafar Ahmad Rather; Mubashir Maqbool; Tabassum Ara; Zahoor Ahmad; Syed Khalid Yousuf
Journal:  Medchemcomm       Date:  2017-12-06       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.